Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' — This Psychedelic Bio-Tech Company Hopes To Help Build That Future ↗

February 05, 2024

Via Benzinga

FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000 ↗

January 31, 2024

FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address...

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗

January 30, 2024

The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.

Via Talk Markets

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

January 24, 2024

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

Via FinancialNewsMedia

5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗

January 13, 2024

The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.

Via Talk Markets

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued ↗

January 11, 2024

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The...

Via Benzinga

Why Is Clearmind (CMND) Stock Up 40% Today? ↗

January 10, 2024

The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing.

Via InvestorPlace

MindMed Announces Business Update and Anticipated Milestones for 2024

January 08, 2024

From Mind Medicine (MindMed) Inc.

Via Business Wire

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Psychedelic Stock Gainers And Losers From January 1, 2024 ↗

January 01, 2024

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psychedelic Drug Stocks Index Up In December; Down YTD ↗

December 27, 2023

The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.

Via Talk Markets

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psychedelic Drug Stocks Index Declined 1.6% This Week ↗

December 17, 2023

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

Via Talk Markets

Topics ETFs

Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed ↗

December 14, 2023

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no...

Via Benzinga

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

December 14, 2023

From Mind Medicine

Via Business Wire

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗

December 10, 2023

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

Via Talk Markets

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex ↗

December 02, 2023

The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.

Via Talk Markets

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

GH Research, Compass Pathways Among Top Psychedelic Movers Of Today ↗

November 23, 2023

Via Benzinga

GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗

November 23, 2023

The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.

Via Talk Markets

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart ↗

November 11, 2023

Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...

Via Talk Markets

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗

November 05, 2023

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.

Via Talk Markets

MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved ↗

November 03, 2023

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.